Bleomycin Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is supplied as bleomycin sulfate, a fermentation-derived glycopeptide antineoplastic standardized by microbiological potency against the WHO International Standard and by chromatographic composition against the current United States Pharmacopeia or European Pharmacopoeia monograph. The product is received as a lyophilized powder for parenteral reconstitution and as a dry-blending grade for tableting, capsule filling, and granule production. Both grades carry the same compendial identity, but injectable and oral solid-dose presentations are differentiated by sterility, endotoxin budget, residual moisture, particle size, and container closure requirements.

Site-specific traceability may be assigned through manufacturer item codes BLEO-S-API for sterile injectable lyophilizate and BLEO-PG-API for oral solid-dose processing powder. These codes are not pharmacopeial classifications and must not replace the official name “Bleomycin Sulfate” in regulatory submissions. The product is released only after the certificate of analysis documents conformity to the appropriate pharmacopeial monograph, regional good manufacturing practice requirements, and the risk controls described in ICH Q3C, ICH Q3D, and ICH M7 where applicable.

Compendial Release Matrix and Pharmacopoeial Boundaries

The following release matrix separates injectable-grade bleomycin sulfate from non-sterile oral solid-dose processing powder. The matrix is based on current compendial methods and does not replace the applicant’s product-specific validation data.

Bleomycin sulfate is a multicomponent glycopeptide in which bleomycin A2 and bleomycin B2 are the principal active species. The pharmacopeial monograph therefore requires more than a single HPLC purity value: lot release includes separate quantitation of related bleomycins, copper-associated forms, and degradation products. The copper-binding region of bleomycin is not treated as an ordinary elemental impurity because the Cu(II)-bleomycin complex participates in oxygen activation and DNA strand scission; nevertheless, free copper outside specification may indicate process deviation or degradation of the coordination environment.

For injectable material, the powder is produced by freeze-drying a sterile-filtered aqueous solution in an aseptic filling line. The final container is sealed under reduced moisture ingress, and container closure integrity is verified during stability studies using methods aligned with USP <1207>. Non-sterile oral solid-dose powder is manufactured in a contained facility with negative-pressure milling and blending suites because bleomycin sulfate is a potent cytotoxic agent requiring control of airborne exposure and cross-contamination.

Why Does Oral Bleomycin Sulfate Not Achieve Reliable Systemic Exposure?

Bleomycin sulfate is a hydrophilic glycopeptide that undergoes rapid proteolytic cleavage in the gastrointestinal lumen. The molecule contains saccharide and peptide bonds that are substrates for intestinal brush-border enzymes, and no specific transcellular uptake process has been identified that would deliver intact bleomycin to the systemic circulation at therapeutically relevant concentrations. Oral bleomycin tablets, capsules, or granules therefore cannot be regarded as interchangeable with intravenous, intramuscular, subcutaneous, or intracavitary administration. Published human pharmacokinetic data for this specific oral configuration is limited, and no compendial monograph for oral bleomycin tablets exists as a recognized therapeutic standard.

The oral solid-dose form is differentiated for formulation screening, nonclinical disposition studies, or local gastrointestinal investigation rather than systemic therapy. In tablet and capsule development, the low active loading imposes blend uniformity requirements under USP <905>; the acceptance value must be determined using a sampling thief at defined positions in a diffusion mixer or V-blender after defined blending time. Segregation risk can be evaluated with a 0.5 % or lower active blend because the low mass fraction of bleomycin sulfate relative to excipients is a primary source of content nonuniformity.

Direct compression and dry granulation are preferred over aqueous wet granulation because bleomycin sulfate hydrolyzes in aqueous media above neutral pH and at elevated temperature. If wet granulation is unavoidable, the granulation should be performed under controlled pH 4.5–6.0 and vacuum dried at product temperatures not exceeding 30 °C. Published data for aqueous granulation of bleomycin sulfate is limited, and each process change must be supported by related substances trending against the starting API rather than by extrapolation from small-molecule oral drugs.

Tablet and capsule formulations should employ water-soluble diluents with low alkaline surface alkalinity. Stearate lubricants may be used at conventional concentrations, but blending times must be controlled to avoid hydrophobic coating of the soluble API at low drug loading. Dissolution method development for oral dosage presentations may use USP <711> apparatus 2 at 37±0.5 °C; however, no pharmacopeial acceptance criterion for oral bleomycin tablets has been established, and any in vitro dissolution specification must be justified through in vivo or nonclinical correlation data.

For granule-filled capsules, the particle size distribution of the API should be controlled by laser diffraction under USP <429>. A typical processing-grade target of D90 < 20 µm supports content uniformity, but the lyophilized injectable powder should not be micronized as a dry powder because sterile filtration and reconstitution behavior depend on the original lyophilized cake structure and specific surface area.

When Injectable-Grade Powder Must Satisfy Sterility and Endotoxin Budgets

Injectable bleomycin sulfate is released only after the lyophilized product passes USP <71> sterility and USP <85> bacterial endotoxin tests. The endotoxin limit is not fixed arbitrarily; it is calculated from the maximum bolus dose and patient body weight in accordance with the K/M formula used in pharmacopeial endotoxin chapters. A lower endotoxin result in the API allows room for downstream excipients, container closures, and reconstitution devices without exceeding the final product acceptance limit.

The sterile powder is prepared by sterile filtration of the bulk solution through a 0.22 µm membrane filter, followed by lyophilization. The freeze-drying cycle must produce a cake that reconstitutes quickly in water for injection or 0.9 % sodium chloride injection. Residual moisture above 5.0 % may accelerate degradation of the glycopeptide and is therefore controlled by Karl Fischer titration of the final container. After reconstitution, the solution pH should remain between 4.5 and 6.0, and visible particulate matter must meet compendial requirements for small-volume parenterals.

Bleomycin sulfate solution is incompatible with strong alkaline buffers, reducing agents containing sulfhydryl groups, and concentrated chelating solutions that may strip copper from the active coordination site. Reconstitution should be performed with non-alkaline diluents; once reconstituted, the injection should be stored at 2–8 °C and used within the stability window established in the product-specific data. Published data for bleomycin sulfate injection indicates that prolonged exposure to room temperature or light in solution increases the formation of polar degradation products, and the material should therefore be protected from light from receipt through administration.

Subvisible particulate and container closure integrity are assessed during stability using USP <788> and USP <1207> as applicable. Injectable-grade API is not interchangeable with oral processing powder because the sterile lyophilizate has a defined headspace gas, moisture, and container integrity profile; reprocessing or repacking into unvalidated containers invalidates the sterility and endotoxin release status.

Differences From Other Antineoplastic APIs and Non-Pharma Bleomycin Grades

Bleomycin sulfate differs from alkylating agents, antimetabolites, and anthracyclines in mechanism, route handling, and dose-limiting toxicity. The compound generates oxygen radical damage through a metal-dependent reaction that produces DNA strand scission, whereas cyclophosphamide requires metabolic activation and methotrexate inhibits folate metabolism. At standard doses, bleomycin is less myelosuppressive than many cytotoxic agents; the principal dose-limiting toxicity is pulmonary inflammation and fibrosis. The risk rises with cumulative exposure, particularly above 400–450 units, and is increased by renal impairment, prior thoracic irradiation, and high inspired oxygen concentrations during anesthesia.

Research-grade bleomycin sulfate or animal-study material may be sold without compendial release, without sterile injectable processing, and without endotoxin control. Those grades are not acceptable for pharmaceutical manufacturing. The pharma grade API described here is released against the current compendial assay, related substances, residual solvent, elemental impurity, and microbiological criteria applicable to the intended dosage form.

Handling of oral solid-dose processing powder requires cytotoxic containment. Gowns, double nitrile gloves, and high-efficiency particulate air filter masks should be used because the penultimate powder mixture and granulation steps can generate respirable dust. Equipment such as tablet presses, capsule fillers, and roller compactors should be isolated or vented with validated wipe-cleaning procedures because traces of bleomycin sulfate must not cross-contaminate non-cytotoxic products. The powder must be stored in tightly closed containers at 2–8 °C, protected from light, and desiccated when the oral solid-dose grade moisture specification is tighter than the ambient warehouse dew point.

The final application scenario is the specification transfer from API to finished drug product. The injectable presentation must retain the release profile through sterilization-grade filtration and lyophilization; the oral solid-dose presentation must preserve blend uniformity through direct compression or dry granulation without inducing hydrolysis. Each presentation is valid only when the manufacturer’s process validation data demonstrate that the API lot-to-lot variation remains within the pharmacopeial acceptance ranges for potency, related substances, and moisture.